Standardized Microbiota Transplant Therapy in Crohn's Disease

Inclusion Criteria: * Able and willing to provide informed consent. * 18-89 years of age. * English speaking. * Diagnosis of CD based on typical clinical and histologic features. * Active disease on endoscopy: * SES-CD \>= 6 * SES-CD \>= 4 for isolated ileal disease * Current CD therapies are in the maintenance phase of dosing at the time of randomization. * Any ongoing CD therapy (apart from steroid use) must be at stable doses for 4 weeks prior to randomization and remain stable over study course. * Steroid use 20mg or less by 5 days prior to randomization. * Steroid use stipulations: * Prednisone must be tapered below 20mg after 7 days. * Any use of budesonide over the study period is allowed although tapering is encouraged. * Rescue medications: Steroid courses (up to 40mg for two weeks with a planned taper) are allowed at the discretion of the treating provider. Study drug therapy will be stopped on a case-by-case basis on discussion with the participant and treating provider. * Women who are not post-menopausal (at least 12 months of non-therapy induced amenorrhea) or surgically sterile (e.g., absence of ovaries and/or uterus) must remain abstinent or use a highly effective form of birth control (e.g., oral contraception, transdermal patch, barrier, intrauterine device). o Periodic abstinence and early withdraw are not acceptable methods. * Able to comply with study measures in the opinion of the investigator. Exclusion Criteria: * Extensive bowel resection: i.e., subtotal colectomy or substantial removal of small bowel where short bowel syndrome could be a concern. * Documented gastroparesis * History of pylorus non-preserving gastric surgery, e.g., Roux-en-Y gastric bypass. * Symptomatic stricture defined as a stricture that: * Cannot be traversed by the colonoscope, * Requires intervention to be traversed, * Is otherwise responsible for the predominant clinical picture, in the opinion of the investigator. * Presence of ileostomy or colostomy. * Entero-vesicular fistula (i.e., fistula from bowel to bladder). * Suspicion of ischemic colitis, radiation colitis or microscopic colitis. * Diagnosis of ulcerative colitis. * Active or untreated infection. * Adenomatous polyps that have not been removed. * Use of antibiotics within 14-days of randomization. * Current pregnancy. * Current breastfeeding or planning to breastfeed over the study period. * History of anaphylactic food allergies. * End stage liver disease or cirrhosis. * Anticipated need for antibiotics over the study period. * Anticipated surgical procedure over the study period. * An absolute neutrophil count \<500 cell/µL. * Diagnosis of a primary immunodeficiency. * Active malignancy requiring the use of chemotherapeutic agent (except for localized non-melanomatous skin cancers). * Patients receiving active cytotoxic therapy for solid tumors and hematologic malignancies. * Any solid organ transplant within 6 months of randomization. * Use of chimeric antigen receptor T-cell therapy or hematopoietic cell transplant within the past 12 months * Life expectancy \<=6 months.